FMP
HilleVax, Inc.
HLVX
NASDAQ
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
1.86 USD
0.03 (1.61%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Robert M. Hershberg M.D., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.hillevax.comexchange
NASDAQ
Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
CIK
0001888012
ISIN
US43157M1027
CUSIP
43157M102
Address
75 State Street
Phone
617 213 5054
Country
US
Employee
90
IPO Date
Apr 29, 2022
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
HLVX Financial Summary
CIK
0001888012
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
43157M102
ISIN
US43157M1027
Country
US
Price
1.86
Beta
0.77
Volume Avg.
189.6k
Market Cap
92.64M
Shares
-
52-Week
1.55-20.22
DCF
4.08
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.6
P/B
-
Website
https://www.hillevax.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest HLVX News
It looks like there's no news available.
